Please assess the completion status of the following clinical trial:

Trial Title: Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. be between age 45 and 80 years of age~2. be able to communicate effectively with study personnel~3. ECOG is \< or = 2~4. screening serum total testosterone\> or = 150ng/dL~5. have prostate cancer, confirmed by pathology report~6. have not been treated with androgen deprivation therapy(chemical or surgical~7. have a clinical indication for the initiation of androgen deprivation therapy~8. give written informed consent prior to any study specific procedures~9. subject must agree to use acceptable methods of contraception~Exclusion Criteria:~1. known hypersensitivity or allergy to estrogen or estrogen like drugs~2. a clinically significant concurrent illness or psychological, familial, sociological, geographical or other concomitant condition that would not permit adequate follow-up and compliance with the study protocol~3. history of abnormal blood clotting,Factor V Leiden clotting disorder, thrombotic disease~4. have ALT or AST above 2 times the upper normal limit~5. have alkaline phosphatase greater than 3 times UNL and/or bilirubin levels above 2mg/dL at baseline~6. patients cannot have brain or spinal cord metastases~7. patients cannot have or be at risk for spinal cord compression from bone metastases~8. received an investigational drug within a period of 90 days prior to enrollment in the study~9. received the study medication previously~10. currently taking testosterone, testosterone-like agents, or antiandrogens including 5-alpha reductase inhibitors within 4 weeks of randomization~11. currently taking Saw Palmetto or PC-SPES (the subject may be considered for randomization after a 4 week washout period prior to randomization)~12. have taken diethylstilbestrol or other estrogen products within the previous 12 months prior to randomization~13. have taken body building or fertility supplements within 4 weeks of admission into the study (steroids and steroid like supplements)~14. have a history of cancer other than prostate cancer, superficial bladder cancer (with no recurrence in the last 5 years) and/or non-melanoma carcinoma of the skin~15. QTcB\>480 msec, If the first QTcB reading exceeds 480msec two additional ECGs are to be performed separated at least 5 min apart, then take the average of the three QTcB or readings to determine if the subject satisfies the above criteria. If the average QYcB reading is \>480 msec then the subject is excluded.

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- GTx- 758 1000mg (Type: EXPERIMENTAL): GTx-758/Experimental/ nonsteroidal selective ER alpha agonist
- GTx-758 2000mg (Type: EXPERIMENTAL): GTx-758/Experimental/ nonsteroidal selective ER alpha agonist
- Lupron Depot (Type: ACTIVE_COMPARATOR): Luteinizing Hormone Releasing Hormone Agonist

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval